Lv4
635 积分 2023-08-23 加入
Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?
1天前
已完结
Next-generation ALK inhibitors: is the median the message?
1天前
已完结
The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma
8天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials
18天前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
18天前
已完结
Emerging landscape of KRAS inhibitors in cancer treatment
23天前
已完结
Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)
1个月前
已完结
Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review
1个月前
已完结
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trials
1个月前
已完结
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
1个月前
已完结
皖公网安备34019202002308
